2. Search Result
Search Result
Results for "

LDL oxidation

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

3

Peptides

17

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0339
    Syringic acid

    		Endogenous Metabolite Bacterial Metabolic Disease
    Syringic acid is correlated with high antioxidant activity and inhibition of LDL oxidation.
    Syringic acid
  • HY-14668
    Lomitapide mesylate
    Maximum Cited Publications
    6 Publications Verification

    AEGR-733 mesylate; BMS-201038 mesylate

    		 Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 + T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .
    Lomitapide mesylate
  • HY-N0521
    (-)-Gallocatechin

    		Drug Isomer Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    (-)-Gallocatechin, an epimer of (-)-Epigallocatechin (EGC) (HY-N0225), is contained in various tea products. (-)-Gallocatechin demonstrates antioxidant activity in vitro, including inhibition of LDL oxidation and DPPH radical scavenging .
    (-)-Gallocatechin
  • HY-113110
    Cysteinylglycine

    L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .
    Cysteinylglycine
  • HY-N0859
    Schisanhenol

    Schizanhenol; Gomisin-K3

    		 UGT Cholinesterase (ChE) Tau Protein SOD Sirtuin Neurological Disease Inflammation/Immunology Cancer
    Schisanhenol (Schizanhenol), a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration .
    Schisanhenol
  • HY-113269
    alpha-CEHC
    1 Publications Verification

    		 Drug Metabolite Others
    alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .
    alpha-CEHC
  • HY-125039
    N-Acetyl lysyltyrosylcysteine amide
    2 Publications Verification

    		 Glutathione Peroxidase Cardiovascular Disease Neurological Disease
    N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation .
    N-Acetyl lysyltyrosylcysteine amide
  • HY-W778608
    Quercetin 7-glucuronide
    1 Publications Verification

    Quercetin 7-O-β-glucuronide

    		 Drug Metabolite Inflammation/Immunology
    Quercetin 7-glucuronide (Quercetin 7-O-β-glucuronide), a metabolite of Quercetin (HY-18085), can be isolated from Madagascarian Uncarina species. Quercetin 7-glucuronide can inhibit LDL oxidation .
    Quercetin 7-glucuronide
  • HY-N0339R
    Syringic acid (Standard)

    		Reference Standards Endogenous Metabolite Bacterial Metabolic Disease
    Syringic acid (Standard) is the analytical standard of Syringic acid. This product is intended for research and analytical applications. Syringic acid is correlated with high antioxidant activity and inhibition of LDL oxidation.
    Syringic acid (Standard)
  • HY-P1997
    Ferrichrome Iron-free

    Desferrichrome; DFC; N-Desferriferrichrome

    		 Biochemical Assay Reagents Others
    Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.
    Ferrichrome Iron-free
  • HY-N3596
    Cleomiscosin C

    Aquillochin

    		 Others Inflammation/Immunology
    Cleomiscosin C (Aquillochin) can be isolated from Aquilaria agallocha. Cleomiscosin C has antioxidant activity. Cleomiscosin C inhibits LDL oxidation and free radicals generation .
    Cleomiscosin C
  • HY-N10638
    N-Acetyldopamine dimer-2

    		Reactive Oxygen Species (ROS) NF-κB Inflammation/Immunology
    N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .
    N-Acetyldopamine dimer-2
  • HY-120651
    LDL-IN-2

    		LDLR Metabolic Disease
    LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .
    LDL-IN-2
  • HY-113110A
    Cysteinylglycine TFA

    L-Cysteinylglycine TFA; Cys-Gly TFA; H-Cys-Gly-OH TFA

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc [1][2][3][4].
    Cysteinylglycine TFA
  • HY-W791754
    Paeonolsilate sodium

    		NF-κB Cardiovascular Disease
    Paeonolsilate (sodium) can inhibit ox-LDL-induced macrophage foam cell formation and inflammation in atherosclerosis. Paeonolsilate (sodium) inhibits NF-κB activation and oxidative stress response induced by ox-LDL. Paeonolsilate (sodium) can be studied in anti-atherosclerosis research .
    Paeonolsilate sodium
  • HY-N15706
    Luteolin-7-O-β-D-glucuronide methyl ester

    		LDLR Cardiovascular Disease Metabolic Disease
    Luteolin-7-O-β-D-glucuronide methyl ester is a flavonoid with antioxidative activity. Luteolin-7-O-β-D-glucuronide methyl ester exhibits potent antioxidative activity with an IC50 of 3.05 μg/mL in the NBT superoxide scavenging assay. Luteolin-7-O-β-D-glucuronide methyl ester inhibits LDL oxidation induced by Cu 2+ with the IC50 value is 71.13 μg/mL .
    Luteolin-7-O-β-D-glucuronide methyl ester
  • HY-113110R
    Cysteinylglycine (Standard)

    L-Cysteinylglycine (Standard); Cys-Gly (Standard); H-Cys-Gly-OH (Standard)

    		 Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (Standard) is the analytical standard of Cysteinylglycine. This product is intended for research and analytical applications. Cysteinylglycine is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .
    Cysteinylglycine (Standard)
  • HY-119265
    LDL-IN-4

    		Acyltransferase Metabolic Disease
    LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .
    LDL-IN-4
  • HY-W778608R
    Quercetin 7-glucuronide (Standard)

    Quercetin 7-O-β-glucuronide (Standard)

    		 Drug Metabolite Reference Standards Inflammation/Immunology
    Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Quercetin 7-glucuronide (Standard)
  • HY-118486
    LDL-IN-1

    		Acyltransferase Metabolic Disease
    LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC50 = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC50s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research .
    LDL-IN-1
  • HY-123016A
    (±)9-HODE cholesteryl ester

    		Endogenous Metabolite Metabolic Disease
    (±)9-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL.2 Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 9-HODE cholesteryl ester.
    (±)9-HODE cholesteryl ester
  • HY-165512
    Nicanartine

    		LDLR Cardiovascular Disease
    Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).
    Nicanartine
  • HY-N0339S
    Syringic acid-d6

    		Bacterial Endogenous Metabolite Metabolic Disease
    Syringic acid-d6 is the deuterium labeled Syringic acid . Syringic acid is correlated with high antioxidant activity and inhibition of LDL oxidation .
    Syringic acid-d6
  • HY-W747575
    (+/-)13-HODE cholesteryl ester

    		Endogenous Metabolite Metabolic Disease
    (±)13-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 13-HODE cholesteryl ester.
    (+/-)13-HODE cholesteryl ester
  • HY-167870
    Piceatannol 4'-O-glucoside

    		LDLR Inflammation/Immunology
    Piceatannol 4'-O-glucoside is an antioxidant. Piceatannol 4'-O-glucoside is active against oxidation of the human LDL. Piceatannol 4'-O-glucoside can be isolated from Mexican Bamboo .
    Piceatannol 4'-O-glucoside
  • HY-N0859R
    Schisanhenol (Standard)

    Schizanhenol (Standard); Gomisin-K3 (Standard)

    		 UGT Reference Standards Cholinesterase (ChE) Tau Protein SOD Sirtuin Neurological Disease Inflammation/Immunology Cancer
    Schisanhenol (Standard) (Schizanhenol (Standard)) is the analytical standard of Schisanhenol (HY-N0859). This product is intended for research and analytical applications. Schisanhenol, a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration.
    Schisanhenol (Standard)
  • HY-137390A
    (3S,5R)-Fluvastatin potassium

    		HMG-CoA Reductase (HMGCR) Cardiovascular Disease Metabolic Disease
    (3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
    (3S,5R)-Fluvastatin potassium
  • HY-106621A
    AL 0671

    		Potassium Channel Metabolic Disease
    AL 0671 is a potassium channel opener. AL 0671 can inhibit nonenzymatic glycation of protein and LDL oxidation. AL 0671 can be used for the researches of cardiovascular and metabolic disease, such as hypertensive diabetes .
    AL 0671
  • HY-182603
    BO-653

    		Drug Derivative Reactive Oxygen Species (ROS) HCV Infection Inflammation/Immunology
    BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC50 of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection .
    BO-653
  • HY-N12385
    Hispaglabridin B

    (R)-Hispaglabridin B

    		 FOXO Others
    Hispaglabridin B is an anti-oxidant agent that can be isolated from Glycyrrhiza glabra. Hispaglabridin B exhibits potent peroxynitrite scavenging activity with an IC50 of 3.2 μM, and shows activity in a low-density lipoprotein (LDL) oxidation system . Hispaglabridin B is also a FoxO1 inhibitor . Hispaglabridin B improves muscle wasting by inhibiting catabolism in vivo and in vitro.
    Hispaglabridin B
  • HY-182569
    FR 111142

    		VEGFR Inflammation/Immunology Cancer
    FR 111142 is an angiogenesis inhibitor (IC50 = 18.4 μM) and has anti-inflammatory activity (IC50 = 20.6 μM). FR 111142 inhibits capillary-like tube formation as well as nitric oxide production in LPS (HY-D1056)-activated murine macrophages. FR 111142 enhances catabolism of low-density lipoprotein (LDL). FR 111142 does not induce significant cytotoxicity in human endothelial progenitor cells, nor affect cell viability of murine macrophages. FR 111142 can be used for the research of cancer, inflammatory diseases .
    FR 111142
  • HY-182469
    FuBIG

    		Lactate Dehydrogenase AMPK FOXO Interleukin Related Reactive Oxygen Species (ROS) TNF Receptor Bcl-2 Family Caspase Apoptosis Neurological Disease
    FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation .
    FuBIG
  • HY-N11846
    4′-O-Methylglabridin

    		Apoptosis Caspase Inflammation/Immunology Cancer
    4′-O-Methylglabridin is an apoptosis inducer with antioxidant, cell cycle-disrupting and anticancer cytotoxic activities. 4′-O-Methylglabridin inhibits various cancer cell lines including liver cancer, breast cancer and colorectal cancer cell lines. By reducing the expression levels of phosphorylated Rb (Ser807/811) and p21 proteins, 4′-O-Methylglabridin promotes cell accumulation at the subG1 and G2/M phases, and triggers caspase-dependent apoptosis via cytochrome C release and caspase-9 activation. 4′-O-Methylglabridin also exerts antioxidant effects by inhibiting lipid peroxide levels and reducing β-carotene consumption, thereby blocking LDL oxidation. 4′-O-Methylglabridin can be used in the research of various cancers and atherosclerotic diseases .
    4′-O-Methylglabridin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: